CLINICAL_TRIALS
trial_result
· 2013-06-21
Clinical Trial Update: Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia [Phase 2]
Summary
A Phase 2 trial evaluating arsenic trioxide for relapsed or refractory acute lymphoblastic leukemia has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Eastern Cooperative Oncology Group | Conditions: Leukemia | Phase 2 | Status: COMPLETED